To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients (ANAREN)

Ipsen

Status: Completed

Conditions: Prostate Cancer

Treatments: Drug: LHRH analogues

Study type: Observational

Funder types: Industry

Identifiers

NCT03017313

A-ES-52014-224

Details and patient eligibility

About

The purpose of the study, is to determine the percentage of patients for whom the initial LHRH prescription has been renewed

Enrollment: 510 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult men diagnosed of locally advanced or metastatic prostate cancer scheduled to receive androgen deprivation therapy with a 3 or 6 month LHRH analogue including those requiring neo-adjuvant or adjuvant androgen deprivation therapy in association with radiotherapy
• Patients having provided written informed consent
• Patients mentally fit for completing a self-administrated questionnaire

Exclusion criteria

• Patients participating in another clinical study at the time of inclusion
• Patients with another severe malignant disease
• Life expectancy of less than 12 months
• Patients already treated with a LHRH analogue within the last year